The regular use of agonists of the μ-opioid receptor for acute pain relief usually leads to tolerance, respiratory depression, constipation and importantly, abuse potential.
Researchers from Atyr Pharma Inc. presented preclinical efficacy data of ATYR-0101, a potential therapeutic biologic based on a domain appended to aspartyl-tRNA synthetase (DARS) in models of lung and kidney fibrosis. By targeting latent-transforming growth factor beta-binding protein 1 (LTBP-1), ATYR-0101 induced apoptosis in myofibroblasts which play a central role in fibrosis and tissue remodeling.
Researchers from Engrail Therapeutics Inc. recently described the pharmacological characterization of ENX-105, a new class of molecule that combines 5-HT1A/2A receptor agonism with D2/3 receptor antagonism, to be used for its antianhedonic and antipsychotic effects.
Cancer immunotherapies are highly effective treatments for treating hematological malignancies, but usually tied to systemic toxicity, including cytokine release syndrome (CRS).
The endocannabinoid system is involved in pain perception, cognition and mood regulation among other functions. The dysregulation in synthesis and degradation of endocannabinoids results in anxiety, depression or degenerative diseases.
KAT2A is a histone acetyltransferase that functions as a transcriptional activator which, together with its paralogue KAT2B, is markedly overexpressed in acute myeloid leukemia (AML) compared to in hematopoietic progenitor cells.
Interleukin-18 (IL-18) is a pro-inflammatory cytokine that modulates innate and adaptive immune responses. Decoy-resistant IL-18, DR-18, from Simcha Therapeutics Inc., is an engineered IL-18 cytokine able to interact with the IL-18 receptor but resistant to IL-18-binding protein (IL18BP), which is a negative regulator of IL-18 signaling, thus overcoming the antitumoral efficacy limitation seen with recombinant IL-18.
Kura Oncology, Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor ziftomenib showed encouraging data across multiple studies, the most encouraging of which were in combination with other standard of care therapies in patients with NPM1-mutant and KMT2A-rearranged acute myeloid leukemia.
Cathepsin G (CTSG) is overexpressed and aberrantly localized for antigen presentation on acute myeloid leukemia blasts and stem cells compared to normal hematopoietic progenitors. Earlier this year, Crossbow Therapeutics Inc. announced the nomination of its first development candidate, CBX-250, a TCR-mimetic (TCRm) bispecific T-cell engager (TCE) antibody targeting a CTSG peptide-human leukocyte antigen (pHLA) complex and CD3.
RSS
.webp?height=488&t=1670008838&width=650 "Acute myeloid leukemia")